Concert Pharmaceutical’s research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with moderate-to-severe alopecia areata. This research will inform future trials and is important in understanding the effects of a single daily dosage compared to two. The treatment process will last 24 weeks is expected to be completed later this year.
Follow this link for the full article: http://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-announces-initiation-open-label-trial
